NK-1 antagonist

Vanda Initiates Thetis Trial for GLP-1 Vomiting Prevention

WASHINGTON, April 8, 2026 Vanda Pharmaceuticals Inc. has announced the initiation of the Thetis clinical trial evaluating NEREUS™ (tradipitant)...

By cGxPwire Editor
April 9, 2026

.Clinical .gov

FDA Advances Tradipitant Review for Motion Sickness Relief

Washington, D.C., November 28, 2025 In a significant regulatory development, Vanda Pharmaceuticals Inc. has announced major progress on tradipitant,...

By cGxPwire Editor
December 1, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

NK-1 antagonist

Vanda Initiates Thetis Trial for GLP-1 Vomiting Prevention

FDA Advances Tradipitant Review for Motion Sickness Relief